Mar 25, 2020
Sosei Heptares Announces New Board Director Appointment and Executive Promotion
Jan 13, 2020
Sosei Heptares: Significant Progress by Orexia and Inexia With Orexin Agonist Program Triggers Next Tranche of Funding From Medicxi
Dec 24, 2019
Sosei Heptares Announces Nomination of a Third Clinical Candidate by Pfizer from Multi-target Drug Discovery Collaboration
Dec 23, 2019
Sosei Heptares Announces the First Phase I Clinical Start From Its Multi-target Drug Discovery Collaboration With Pfizer
Nov 28, 2019
Sosei Heptares Announces That the COPD Treatment Ultibro® Breezhaler® has been Included in the National Reimbursement Drug List in China
Nov 19, 2019
Sosei Heptares Creates New World-Class International Scientific Advisory Board to Support Strategic Decision-Making Aligned with Corporate Objectives
Nov 12, 2019
Sosei Heptares Operational Highlights and Consolidated Results for the Nine Months Ended 30 September, 2019
Oct 09, 2019
Sosei Heptares to Receive US$3 Million Payment from Genentech on Nomination of a New GPCR Disease Target
Oct 01, 2019
Sosei Heptares Notes the Announcement of Positive Results from Phase III IRIDIUM Study of Inhaled Combination QVM149 in Patients with Uncontrolled Asthma
Sep 12, 2019
Sosei Heptares Investor R&D Event Highlights Innovative Research and Development Approaches and Strong Pipeline Momentum
Aug 05, 2019
Sosei Heptares and Takeda Enter Into New Strategic Multi-target Research, Development and Commercialization Partnership
Jul 16, 2019
Sosei Heptares Enters Into Multi-target Research Collaboration and License Agreement With Genentech
Jun 10, 2019
Sosei Heptares to Receive New $3 Million Milestone Payment from Pfizer, as It Advances a Second Candidate from the GPCR Collaboration for Clinical Development
May 23, 2019
Sosei Heptares Notes That a Valid Marketing Authorization Application For QVM149, a Potential New Inhaled Combination Therapy For Asthma, Has Been Filed With the European Medicines Agency
Feb 20, 2019
Sosei Heptares Starts New Clinical Development Program
Feb 04, 2019
Sosei Heptares Announces Medicxi to Invest Up To EUR40 Million in New Collaboration Based on its Orexin Agonist Program
Jan 31, 2019
Sosei Heptares to Launch ORAVI® Mucoadhesive Tablets 50mg for Oropharyngeal Candidiasis in Japan
Jan 07, 2019
Sosei Heptares to Receive US$15 Million Milestone Payment From AstraZeneca With First Partnered Program Moving Towards Phase 2
Dec 13, 2018
Sosei Heptares Starts New Clinical Development Program - First Subject Dosed in Phase I Study of HTL0014242, a Selective mGlu5 Negative Allosteric Modulator in Development to Treat Psychiatric and Neurological Disorders
Dec 12, 2018
Sosei Group Corporation Announces Changes in Executive Management team - Shinichi Tamura Appointed as Chairman, President & Chief Executive Officer